WHO’s ACT-Accelerator facing funding issue
By Ishika Sahni
On September 11, “Access to COVID-19 Tools Accelerator” (ACT), A global collaboration initiated by the World Health Organization (WHO) for speed up the development, production and fair deployment of Coronavirus diagnostics, therapeutics and vaccines. In this project, initiated by WHO there is a problem of funding.
WHO Director-General Tedros Adhanom Ghebreyesus said, “We are still facing a funding gap of $35 billion”. He also added in a press briefing on Thursday “ACT Accelerator has received $2.7 billion only from which they had enabled robust start-up phase-only’’. The amount is less than 10% of the amount only. The ACT-Accelerator will not be able to achieve their goals without the increase in funding. They have to start up clinical trial and manufacturing, licensing and regulation capacity. The ACT-Accelerator endures research into ensuring vaccines, therapeutics and diagnostics.
WHO had registered 180 vaccines in development, counting 35 in a human trial. Tedros said “the world’s objective to develop tools as soon as possible must be matched by its objective to certify that as many people as possible have to retrieve them’’. The Facilitation Council of the ACT- Accelerator met for the first time to allocate political leadership and advocacy to deploy advanced resources. The leader of Norway, Rwanda, South Africa and the European Union expressed their support at the meeting. Last month six COVID19 vaccine candidates entered into the third phase of the trial. So there is a hope that we will get the vaccine by year-end.